Alzheimer’s setback: Wegovy fails to slow disease in big trial
Alzheimer’s setback: Wegovy fails to slow disease in big trial
New Alzheimer’s setback as Novo Nordisk reports GLP-1 drug semaglutide failed to slow disease progression in Evoke trials, despite biomarker improvements.
The Evoke trials of semaglutide, the active ingredient in Wegovy, did not slow the progression of Alzheimer’s disease. While researchers observed improvements in biomarkers linked to the condition, these changes did not translate into a measurable slowdown in cognitive or functional decline. The news marks a significant setback for the idea that a GLP-1 drug could be repurposed to tackle dementia as well as obesity and diabetes.
Participants in the studies were aged between 55 and 85 and had either mild cognitive impairment or mild dementia due to Alzheimer’s disease. Progression was tracked through a combination of clinical tests and structured interviews. The absence of a slowing signal despite biomarker shifts underscores the complexity of Alzheimer’s and the likelihood that multiple biological processes must be addressed simultaneously.
Experts noted that GLP-1 medicines have demonstrated clear benefits for weight management and metabolic health, and that real-world data from private prescriptions could still reveal longer-term effects. They also stressed that the field must pursue multi-pronged strategies rather than a single solution, as real progress against Alzheimer’s will likely require combinations of therapies targeting different disease pathways.
Looking ahead, researchers say the setback should not derail the broader effort to develop disease-modifying treatments for Alzheimer’s. The focus will shift toward better understanding how GLP-1 drugs interact with the brain, how to combine therapies safely, and how to collect robust real-world evidence to guide future trials.
Cover image source: Weight-Loss Drugs Don’t Appear to Work Against Alzheimer’s 🔗
